Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | GRK2 | P25098 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | GRK3 | P35626 | 1/20 | 0.40 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256074 | 0.86 | NTRK1 (0.39) | NTRK1TLK2RAF1PDGFRBKIT | |
| SCHEMBL3577292 | 0.81 | NTRK3 (0.53) | NTRK1PDGFRBKITFLT4FLT3 | |
| SCHEMBL3577289 | 0.81 | NTRK3 (0.53) | NTRK1PDGFRBKITFLT4FLT3 | |
| SCHEMBL3574416 | 0.80 | KDR (0.35) | NTRK1TLK2KITFLT4FLT3 | |
| SCHEMBL3574418 | 0.80 | KDR (0.35) | NTRK1TLK2KITFLT4FLT3 | |
| SCHEMBL4702560 | 0.79 | CSF1R (0.43) | NTRK1FLT3NPC1RAB9A | |
| SCHEMBL5427717 | 0.79 | CSF1R (0.43) | NTRK1FLT3NPC1RAB9A | |
| SCHEMBL3581916 | 0.79 | CSF1R (0.43) | NTRK1FLT3NPC1RAB9A | |
| SCHEMBL3580637 | 0.77 | PDPK1 (0.47) | NTRK1TLK2RAF1 | |
| SCHEMBL3579599 | 0.77 | KMT2A (0.53) | NTRK1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | NTRK1 4116/4885TLK2 3838/4885HDAC8 220/4885 |
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | NTRK1 307/4885TLK2 304/4885HDAC8 1069/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | NTRK1 4116/4885TLK2 3838/4885HDAC8 220/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | NTRK1 413/4885TLK2 363/4885HDAC8 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.